The super family of glutathione S-transferases (GSTs) is composed of multiple isozymes with significant evidence of functional polymorphic variation. Over the last three decades, data from cancer studies have linked aberrant expression of GST isozymes with the development and expression of resistance to a variety of chemicals, including cancer drugs. This review addresses how differences in the human GST isozyme expression patterns influence cancer susceptibility, prognosis and treatment. In addition to the well-characterized catalytic activity, recent evidence has shown that certain GST isozymes can regulate mitogen-activated protein kinases or can facilitate the addition of glutathione to cysteine residues in target proteins (S-glutathionylation). These multiple functionalities have contributed to the recent efforts to target GSTs with novel small molecule therapeutics. Presently, at least two drugs are in latestage clinical testing. The evolving functions of GST and their divergent expression patterns in individuals make them an attractive target for drug discovery.
widely express transcripts for GSTA1, A2 and A4, whereas expression of GSTA3 is rare and GSTA5 has yet to be detected in human tissues. Epidemiological results show that aberrant expression of GSTa has been linked to an increased risk in colorectal cancer, ovarian cancer and clear cell renal cell carcinoma ; Tetlow et al., 2004a; Chuang et al., 2005) .
The GSTA1 gene contains seven exons and is B12 kb in length. A genetic polymorphism of GSTA1 is characterized by two alleles, GSTA1*A and GSTA1*B (Table 2 ). These alleles differ in promoter regions based on three linked single nucleotide substitutions at positions -567, À69 and -52. Specifically, the -52 substitution has been shown to increase promoter activity in GSTA1*A, thus making it more highly expressed. Coles et al. (2001) previously showed a correlation between GSTA1*B expression and an increased risk of colorectal cancer. However, as with many such published accounts, other groups have recently reported conflicting evidence finding no association between GST expression and susceptibility to colorectal cancer (van der Logt et al., 2004) . GSTA2 has not been extensively studied, but it is known to have several variants (GSTA2*A-E). Single nucleotide polymorphisms for GSTA2 are summarized in Table 2 . The catalytic properties of GSTA2 variants A-D do not seem to differ; however, the novel variant GSTA2E shows reduced rates of catalysis when compared to A-D (Ning et al., 2004) . This may be due to substitution of the highly conserved Pro residue (Ning et al., 2004) .
GSTA3-3 is selectively expressed in steroidogenic tissues and plays a role in steroid hormone biosynthesis (Johansson and Mannervik, 2001 ). Three GSTA3 transcripts have been identified along with a p.I71L polymorphism found exclusively in African populations (Tetlow et al., 2004a) . Polymorphisms in GSTA3 may affect steroidogenesis through altered protein levels or function, and it has recently been hypothesized that alterations in genes involved in steroidogenesis and sex steroid metabolism could potentiate risk factors for the development of ovarian cancer (Tiltman and Ali, 2001; Tetlow et al., 2004a) .
Omega class
The Omega class of GSTs contains two members (GSTO1 and GSTO2) and a pseudogene (GSTO3p). Based on two defining features, the Omega class is both structurally and functionally distinct from other eukaryotic GSTs (Townsend and Tew, 2003) . First, X-ray crystallography shows a unique 19-residue N-terminus extension that forms a structural unit quite unlike any found in other classes. At present, its function remains undefined (Board et al., 2000) . Second, known substrates of other GSTs are not catalysed by GSTO.
GSTO1 is a single gene located on chromosome 10 that codes for proteins expressed abundantly in the liver, macrophages, glial and endocrine cells (Board et al., Table 2 ) (Board et al., 2000) . Among the Australian, African and Chinese populations, GSTO1*A was the most prevalent haplotype with a frequency ranging from 0.6 to 0.9; whereas GSTO1*B*A was the least common, with a frequency of 0.01-0.05 (Whitbread et al., 2003) . GSTO1*A demonstrated a GSH-dependent reduction of dehydroascorbate, a function characteristic of glutaredoxins rather than GSTs (Board et al., 2000) . This allele was first described as the human monomethylarsenic acid reductase, (MMA[V]), and is the rate-limiting enzyme of inorganic arsenic metabolism (Zakharyan et al., 2001) . Thioltransferase activity differs among the GSTO1*A-C polymorphisms and may contribute to an individual's ability to metabolize arsenic (Tanaka- Kagawa et al., 2003) . GSTO2, while separated from GSTO1 by 7.5 kb on chromosome 10, shares 64% amino-acid identity (Whitbread et al., 2003). GSTO2, like GSTO1, is ubiquitously expressed and shares GSH-dependent dehydroascorbate reductase activity. However, GSTO2 has a high catalytic activity toward CDNB, and its overexpression induced apoptosis, suggesting a possible role in cell signaling .
Zeta class
The Zeta class (GSTZ1) is a single 10.9 kb gene located on chromosome 14 that codes for a 29 kDa protein (Table 1) (Blackburn et al., 1998) . GSTZ1 was independently characterized as maleylacetoacetate isomerase (MAAI) and plays a putative isomerase role in the catabolic pathway of phenylalanine and tyrosine in addition to the GSH-dependent transformation of ahalogenated acids (Fernandez-Canon et al., 2002) . GSTZ1 is preferentially expressed in hepatocytes and renal proximal tubule cells where phenylalanine and tyrosine are catabolized.
While the literature is limiting for this class, GSTZ1 polymorphisms have been identified (GSTZ1*A-D) ( Table 2) (Blackburn et al., 1998 (Blackburn et al., , 2001 ). The isozyme GSTZ1*A has the highest catalytic activity toward dichloroacetic acid, an investigational drug for certain metabolic disorders and a nephrotoxic metabolite of industrial solvents (Board et al., 2000; Guo et al., 2005) . In contrast, GSTZ1*D (p.T82M) has a reduced catalytic activity and has been associated with inborn errors in tyrosine metabolism, although the disorders have also been attributed to mutations in other enzymes. Rodent models deficient for GSTZ1 provide insight into its role in metabolic deficiencies. GSTZ1/MAAI converts maleylacetoacetate to fumarylacetoacetate (FAA). GSTZ1-deficient mice have an elevated urinary excretion of FAA and were subject to renal injury following phenylalanine and tyrosine overload (Fernandez-Canon et al., 2002) . Four families have been identified that have GSTZ1-deficient members that have died within the first year of life. Whereas the clinical data for GSTZ1 are insufficient to deduce a role for GSTZ1 in inherited genetic disease, it is plausible that a perturbation in GSTZ1-mediated tyrosine metabolism is contributory to the described pathology.
Mu class
Five GST isoforms belonging to the mu class (GSTM1-5) have been described (Pearson et al., 1993 Loss of GSTM enzyme function is ascribed to a homozygous deletion of this gene resulting in the GSTM1*0 allele (Smith et al., 1994) . It has been suggested that the mutation is a result of an unequal crossing over of the M1 and M2 loci (Xu et al., 1998) , which are in close physical proximity and share 99% nucleotide sequence identity (Pearson et al., 1993) . The frequency of GTSM1*0 individuals is approximately 67% in Australians, 50% in Caucasians and 22% in Nigerians (Smith et al., 1995) . The GSTM null phenotype is associated with an increased risk of the lung, colon and bladder cancer and has also been associated with response rates to some chemotherapy (Smith et al., 1994; Lohmueller et al., 2003) . For example, GSTM1*0 patients with acute myeloid leukemia (AML) have been shown to have a better response to adriamycin and cyclophosphamide treatment, although precise reasons for this correlation are not clear (Ambrosone et al., 2001) .
Cytosolic prostaglandin E was purified from the human brain and characterized as GSTM2 (Beuckmann et al., 2000) . The GSTM2*B allele has been shown to catalyse the conjugation of GSH to aminochrome, a redox cycling product of dopamine (Baez et al., 1997) . Products formed during the redox cycling of catecholamines (such as dopamine) contribute to the processes involved in neurodegenerative diseases such as Parkinson's disease and schizophrenia; therefore, GSTM2*B may play a cytoprotective role in neurodegeneration (Baez et al., 1997) .
The GSTM3 locus contains two alleles, A and B. The GSTM3*B allele has a three base pair deletion in intron 6 that introduces a recognition motif for the transcrip-tion factor YY1 (Inskip et al., 1995) . GSTM3*A and *B are expressed in the brain; yet, there appears to be no direct relationship between GSTM3 expression and the incidence of astrocytomas (Hand et al., 1996) . The GSTM3*AA genotype is associated with an increased risk for laryngeal squamous cell carcinoma, whereas GSTM3*BB was putatively protective (Matthias et al., 1998) . In addition, GSTM3*AA was shown to occur more frequently in patients with multiple cutaneous basal cell carcinoma than GSTM3*BB (Yengi et al., 1996) .
Recently, two new polymorphisms have been detected in the GSTM3 gene, a rare p.G147W substitution and a more common p.V224I substitution. These two polymorphisms can combine to form four different isoforms (Tetlow et al., 2004b) . The p.W147 variant seems to exhibit decreased catalytic and specific activity, whereas the p.I224 variant has shown increased catalytic and specific activity (Tetlow et al., 2004b) .
Theta class
The Theta class of GSTs consists of two different subfamilies: GSTT1 and GSTT2. Genes encoding both proteins are colocalized on chromosome 22 and are separated by 50 kb (Pemble et al., 1994; Tan et al., 1995) . Polymorphisms exist within both genes including a null phenotype (GSTT1*0) that exhibits decreased catalytic activity and has been associated with an increased risk of cancers of the head, neck and oral cavity (Strange and Fryer, 1999) .
A single nucleotide polymorphism in exon 3 results in two different variants, GSTT1*A and GSTT1*B (Table 2 ). GSTT1*A has a threonine at residue 104, which is substituted to a proline in the GSTT1*B allele (Alexandrie et al., 2002) . The GSTT1*B allele shows a decreased catalytic activity when compared to the GSTT1*A allele, which could be attributed to the conformational change induced by the proline substitution (Alexandrie et al., 2002) .
The presence of a G to A transition at intron 2 has given rise to a pseudogene (GSTT2P) of GSTT2. Evidence points to transcription of this gene, although the gene product is thought to be inactive. An allele identified in GSTT2 involves a rare p.M139L substitution (Coggan et al., 1998) . A phenotype relating to this substitution has yet to be identified, although there is no clear indication that this substitution affects enzyme function (Coggan et al., 1998) .
GST null phenotype and cancer prognosis
Deletion of the GSTM1 and GSTT1 genes results in a 'null' genotype characterized by a general deficit in enzymatic activity. Individuals homozygous for these deletions are thought to be at increased risk for malignancies as a consequence of a decreased capacity to detoxify possible carcinogens. Where this phenotype has been studied as a predictive factor for cancer prognosis or response to therapy, the results have been contingent upon tumor type. Patients with GSTM1*0 or GSTT1*0 showed a better survival rate after chemotherapeutic treatment for invasive ovarian cancer compared to other patients (Howells et al., 2001 ). However, results were contrary for ovarian cancer patients who were double null for GSTM1 and GSTT1. When compared to patients with the wild-type GSTM1 or GSTT1 allele, the null genotype patients exhibited a diminished response to chemotherapy resulting in both a poorer prognosis as well as a decrease in remission rates (Howells et al., 1998) .
The occurrence of acute myelogenous leukemia (AML) is associated with exposure to carcinogenic chemicals, particularly benzene and its derivatives. This association of AML occurrence with carcinogen exposure provides a rationale for examining chemical detoxification enzymes, such as GSTs, in patients with AML (Ye and Song, 2005). Specifically, GSTM1 and GSTT1 phenotypes were examined in patients with AML, and it was shown that patients null for GSTT1 exhibited an increased toxicity and reduced survival rate following chemotherapeutic treatment (Davies et al., 2001) . In contrast to this lower survival rate, patients null for GSTM1 or GSTT1 showed a twofold reduction in cancer relapse during remission (Stanulla et al., 2000) .
GST null genotypes have also been examined when studying patients with chronic myeloid leukemia (CML). A reciprocal chromosomal translocation of t(9;22) results in a BCR-ABL fusion protein that causes a disruption of normal signaling pathways (Mondal et al., 2005) . It is this pathway disruption that is thought to cause the initiation of CML. When comparing CML patients to a control population, a strong correlation was found between CML incidence and the presence of the GSTT1*0 genotype (Mondal et al., 2005) . The frequency of GSTT1*0 in the CML patients varied greatly from the control group, whereas the frequency of the GSTM1*0 genotype did not (Mondal et al., 2005) .
Epidemiological assessment
Small-scale population studies, particularly with cancer patients, are prone to significant limitations. There are numerous correlative reports that fall into this category, and deriving firm conclusions from such data are difficult. What is clear is that a single variable, such as is represented by a GST polymorphism, is not likely to afford a straightforward risk factor for analysis of cancer susceptibility or response to chemotherapy. Multivariables such as carcinogen exposure, pharmacokinetic/pharmacodynamic polymorphisms and population diversities must also be taken into account. This consideration only serves to further complicate the ability to draw consistent conclusions.
The literature is replete with correlative epidemiological reports where small sample size precludes definitive conclusions of cause and effect between GST expression and cancer incidence. As a phase II detoxification enzyme, GST is unlikely to act in isolation. As such, in the absence of multivariant analysis of other metabolic enzymes, any statistical correlations are likely to be oversimplistic. Moreover, the ligand-binding properties of GST (particularly those identified recently for GSTp) will also serve to enhance the level of complexity for any correlative analysis. Collectively, present studies serve to show that levels of GST expression contribute to disease progression and prognosis; however, at best, the data are confusing and sometimes conflicting.
GST Pi
The GST Pi class is encoded by a single gene spanning approximately 3 kb and located on chromosome 11 (Cowell et al., 1988) . Four active, functionally different polymorphisms (GSTP1*A-D) have been identified (Ali-Osman et al., 1997). The GSTP1 genotype has been associated with differences in chemotherapeutic response and cancer susceptibility and is overexpressed in a wide variety of tumors including ovarian, NSCLC, breast, colon, pancreas and lymphoma (Tew, 1994) . GSTP1*A has been reported to play a role in the acquisition of resistance to cisplatin via formation of platinum-GSH conjugates (Goto et al., 1999) . Patients expressing homozygosity for the GSTP1*B allele have a diminished capacity to detoxify platinum-based anticancer agents, thus making this phenotype favorable for response rates (Stoehlmacher et al., 2002 ). An p.I105V substitution in the GSTP1*B allele results in a substantial reduction in catalytic activity and diminished detoxification capacity in individuals possessing the p.V105 as compared to individuals possessing the p.I105 allele (Watson et al., 1998) . GSTP1*C, an allelic variant that is predominant in malignant glioma cells, differs from other GSTP1 variants by two transitions resulting in p.I104V and p.A113V (Lo and Ali-Osman, 1998). Individuals positive for GSTP1*C seem to have a lower incidence of breast cancer (Maugard et al., 2001 ). However, the precise relevance of this variant to disease occurrence or progression is not yet established.
Although it is well established that GSTp is overexpressed in a wide variety of solid tumors, prostate cancer is the only example in which the absence or reduced expression of GSTp is associated with tumor incidence. GSTp is widely expressed in normal prostate tissue; however, its presence is undetectable in malignant cells (Nelson et al., 2001) . Studies examining the absence of GSTp in human prostate cancer show that hypermethylation of the GSTp regulatory region is the most common somatic alteration identified ). This alteration results in the loss of GSTp expression and is proposed to occur during pathogenesis of the disease ( Lee et al., 1994) . Recently, a methyl-CpG binding domain protein has been identified that mediates hypermethylation of the GSTp regulatory region (Bakker et al., 2002) . These findings provide a possible target for restoration of GSTp activity. GST expression (and/or activity) of specific isoforms is lost in some individuals with allelic variation.
Recently, Dang et al. (2005) examined the effect of GSTP1 on the survival and proliferation of human colon cancer cells. GSTP1 wild type and deficient colon cancer cells were grown under serum deprivation and low-density seeding conditions, and cellular apoptosis, oxidative stress and kinase signaling were examined. Lack of GSTP1 expression resulted in an increase in cellular oxidative stress and resultant apoptosis when cells were cultured under growth-limiting conditions (Dang et al., 2005) . In addition, the presence of GSTP1 was essential for the mediation of MAPK kinase and ERK kinase signaling (Dang et al., 2005) . Subsequent in vivo data correlated with the in vitro findings showing that GSTP1 plays a crucial role in early tumorigenesis (Dang et al., 2005) . This study illustrates that GSTP1 is important for human colon cancer cell survival and proliferation, and overall these results show that GSTP1 plays a critical role in protection from cell cycle arrest and oxidative stress under growth-limiting conditions (Dang et al., 2005) .
GSTs and kinase regulation
It has been speculated that the absence or decreased expression of GSTp results in a reduced detoxification of possible carcinogens that may be causal to malignant transformation and disease progression. In addition, the GST-mediated conjugation of GSH to a number of anticancer drug substrates has long been linked to anticancer drug resistance in a variety of tumors. A disparity of this is that GSTp has a weak affinity for the majority of anticancer drugs, although its increased expression is highly correlated with multidrug resistance. From this it can be inferred that the capacity of GSTs to regulate kinase-dependent proliferation pathways, especially in the case of GSTp, may be of more consequence than its catalytic properties alone.
GSTs Another example of GST-mediated kinase regulation is evidence that GSTM1 binds to and inhibits the activity of ASK1 (Cho et al., 2001) . ASK1 is an MAP kinase kinase kinase that activates the JNK and p38 pathways leading to cytokine-and stress-induced apoptosis (Ichijo et al., 1997) . Under normal conditions, ASK1 exhibits low activity because of its sequestration via GSTM1. This protein:protein interaction forms a GSTM1:ASK1 complex, which is dissociated under stressful conditions leading to the release and activation of ASK1 (Figure 2) (Saitoh et al., 1998; Dorion et al., 2002) . This mechanism is similar to the one proposed for GSTp:JNK. In conditions such as oxidative stress or heat shock, GSTM1 oligomerizes allowing for the release of ASK1 and subsequent induction of apoptosis (Dorion et al., 2002) . Impaired clinical response to therapy in a variety of tumor types has been associated with an altered expression of GSTM1. Thus, any enzymatic influence GSTM1 plays in anticancer drug resistance is only further augmented by its role in kinase regulation.
In addition to acting as a negative regulator of kinase activation, GSTp has also been shown to play a necessary role in the glutathionylation of 1-cys peroxiredoxin (1-cysPrx). Oxidation of the catalytic cysteine of 1-cysPrx has been associated with its loss of peroxidase activity (Manevich and Fisher, 2005 activity (Manevich and Fisher, 2005) . From this study, it was concluded that the glutathionylation and subsequent GSH-mediated reduction of 1-cysPrx requires heterodimerization with GSTp (Manevich and Fisher, 2005) . This provides the first example in which GSTp functions in the glutathionylation of oxidized cysteine residues. In addition, our lab has found that cells deficient in GSTP1-1 and/or GSTP2-2 have a reduced capacity to respond to oxidative or nitrosative stress by enacting glutathionylation of a select group of target proteins (Townsend et al., 2005) . These findings imply that GSTp may play a direct role in control of posttranslational glutathionylation reactions.
Pharmacogenetics and GSTs
Epidemiological evidence shows the existence of significant variations in individual patient response to cancer chemotherapy. These variations include altered drug metabolism, genetic polymorphisms and their functional significance, varied exposure to carcinogens, and population diversities such as race and ethnicity. When attempting to design an effective therapeutic regime, it is necessary to consider the different susceptibility and pharmacogenetic factors involved. The complex genetics and expression patterns of GSTs should provide a variable platform for rational drug design and serve to make GSTs an applicable target for anticancer therapy. In tumors where GST overexpression has an adverse effect on therapeutic response, distinct strategies have been adopted to target GSTs. One pharmacological approach is the design of GST inhibitors to increase the efficacy of chemotherapeutics that would otherwise be detoxified by GSTs. Broadly, GST inhibitors can be classified as competitive or non-competitive. Two of the best-characterized inhibitors are ethacrynic acid (EA) and the GSH analog TLK199 [g-glutamyl-S-(benzyl)-cysteinyl-R-phenyl glycine diethyl ester]. EA acts as a non-competitive inhibitor of GSH for GST binding as well as depleting the GSH cofactor by forming an EA-GSH conjugate (Ploemen et al., 1994) . The binding to both GST and GSH serves to inhibit enzyme activity. Our earlier studies have shown this to be effective in sensitizing tumors that otherwise exhibited chemotherapy resistance . TLK199 is a selective inhibitor of GSTp and can also act as a chemosensitizer potentiating the toxicity of numerous anticancer agents in different tumor cell lines. Sensitivity to a range of anticancer drugs, including nitrogen mustards, was enhanced in xenograft models with elevated GST levels ( Morgan et al., 1996) . Because of the structural similarities to GSH, TLK199 has also been shown to effectively inhibit the multidrug resistance-associated protein 1 (MRP-1), reversing the resistance of a variety of agents in NIH3T3 cells transfected with MRP-1 (O' Brien et al., 1999) .
Interestingly enough, TLK199 exhibited myeloproliferative effects in mice during preclinical studies (Ruscoe et al., 2001) . In vitro hematopoiesis experiments showed that mice deficient in GSTp exhibit an increase in myeloid cell differentiation and proliferation (Gate et al., 2004) . The molecular basis for this effect is possibly due to an increase in bone marrow progenitor cells proliferating and differentiating thus increasing production of circulating mature blood cells (Gate et al., 2004) . In addition, a probable cause of these myeloproliferative effects is the ability of TLK199 to disrupt the protein:protein interaction of the JNK:GSTp complex (Adler et al., 1999; Ruscoe et al., 2001; Wang et al., 2001) . As a consequence of this effect, JNK activity is enhanced and, in the case of the bone marrow compartment, this has been causally associated with the increase in cellular proliferation (Gate et al., 2004) .
A new class of 7-nitro-2,1,3,-benzoxadiazole derivatives have been designed as suicide inhibitors of GSTs. These NBDs thioethers have micromolar to nanomolar affinities for binding to the H-site of GSTA1-1, GSTP1-1 and GSTM2-2 ( Ricci et al., 2005) . NDBs have been shown to induce tumor cell death by dissociating the JNK:GSTp complex thus initiating apoptosis . When compared to the earlier example of bone marrow, this serves to illustrate the different role of JNK in transformed cells. A representative model of these NBD derivatives is 6-(7-nitro-2,1,3,-benzoxadiazole-4-ylthio)hexanol or NBDHEX (Ricci et al., 2005) . Their utility as possible anticancer drugs has yet to be established; however, mechanistically their impact upon kinase pathways does conform to literature predictions.
Another newly designed GSTA1-1-specific inhibitor is the GSH conjugate L-g-glutamyl-(S-9-fluorenylmethyl)-L-cysteinyl-glycine (Cacciatore et al., 2005) . This inhibitor possesses a fluorenylmethyl group as a cysteine Sderivatized moiety. It is thought that the H-site of GSTA1-1 will favor the binding of this isoform with a greater affinity, whereas the fluorescent properties will allow for easier monitoring during biological tests (Cacciatore et al., 2005) . L-g-glutamyl-(S-9-fluorenylmethyl)-L-cysteinyl-glycine was shown to be effective in inhibiting GSTA1-1, GSTP1-1 and GSTM2-2 with the greatest inhibition shown against the alpha isoform ( Cacciatore et al., 2005) . Again, any practical utility as an anticancer drug has yet to be established.
Prodrugs Lyttle et al., 1994) . TLK286 is cleaved by a GSTP1*A-promoted b-elimination reaction into a nitrogen mustard and GSH analog that can then alkylate cellular nucleophiles (Morgan et al., 1998) . GSTP1-1 expression is correlated to drug sensitivity both in cell culture and in animal models (Morgan et al., 1998; Rosario et al., 2000) . In addition, GSTP1*A was reported to be adaptively downregulated at both the protein and transcript level following chronic exposure to TLK286 (Rosario et al., 2000) . Collectively, these results serve to support the concept that TKL286 will selectively target tumors expressing high levels of GSTP1*A thus preferentially exerting its cytotoxic effect on these tissues.
A N,N-dimethylamino) diazen-1-ium-1,2-diolate (PABA/NO). GSTp efficiently metabolizes PABA/NO to nitric oxide and has a preferential selectivity to GSTp over GSTa (Findlay et al., 2004) . In addition to releasing nitric oxide, treatment with PABA/NO has been shown to induce activation of p38, JNK and ERK (Findlay et al., 2004) . It has not yet been shown whether kinase activation is caused by direct interaction with NO or interaction with the drug and/or its metabolites; however, this ability to activate stress-related kinases is significant due to the observed function of GSTp as a negative regulatory switch for these kinase pathways. Figure 3 shows the possible S-thiolation intermediates following treatment with nitric oxide releasing drugs such as PABA/NO.
Conclusions and perspectives
Many studies have provided epidemiological linkage of polymorphic expression of GSTs with cancer incidence and prognosis although, at times, the data are fragmented and inconsistent. These inconsistencies serve to emphasize the importance of considering the limitations and variables of each study when attempting to draw any definitive conclusions. GSTs have also been shown to play critical roles in kinase signaling as well as glutathionylation, indicating that their function extends beyond their endogenous catalytic properties. These functions in control of cell signaling and post-translational modification pathways provide novel avenues for exploration of new drugs. It is unlikely that 10 years ago, a myeloproliferative function would have been ascribed to GSTp inhibition. The fact that the importance of S-glutathionylation has yet to be fully appreciated gives credence to the possibility that antagonists/agonists of this pathway may have biological consequences. In addition, the GSTp activated prodrug Telcyta (TLK286) is presently in late-stage 
Reaction of GS(O)NH 2 with GSH forms GSH disulfide-S-oxide (GS(O)SG) or can be further oxidized to sulfinic acid (GS(O)OH) and NH 3 . The key intermediates leading to the synthesis of GS(O)SG are the sulfinamides (GS(O)NH 2 and GS(O)-NH-SG). The reaction of GS(O)SG or GS
Á with a reduced protein thiol (R-SH) leads to the formation of a mixed disulfide. clinical development. The results of Phase III trials should be available in 2006, and these will influence eventual FDA registration of the drug. Obviously, development of such drugs will influence future drug discovery efforts.
